Review of Palliative Radium 223 (223Ra) in metastatic castration resistant prostate cancer (mCRPC): Experience at West Virginia University (WVU) Cancer Center.

CONCLUSION: While the science supporting the development and clinical use of Ra-223 is compelling, optimal clinical benefit will likely require earlier referral for Ra-223, before patients have exhausted most conventional therapies. At WVU, we found that our referred patients had practically all ADT, radiation, and cytotoxic therapy before starting Ra-223. A 2019 report from McMaster University using Ra-223 in 60 men with heavily pre-treated mCRPC also found a median OS of 8.2 months with only 42% completing all six treatment cycles, results almost identical to ours(2). Other studies confirmed that men with less advanced mCRPC, receiving the full course of Ra-223, had better OS(3). Now, we offer Ra-223 to men with symptomatic bone-predominant CRPC but we highly encourage earlier referral. PMID: 33219158 [PubMed - as supplied by publisher]
Source: Journal of Nuclear Medicine Technology - Category: Nuclear Medicine Tags: J Nucl Med Technol Source Type: research